Zhu et al., 2006 - Google Patents
Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related virusesZhu et al., 2006
View PDF- Document ID
- 4169976679932991081
- Author
- Zhu Z
- Dimitrov A
- Chakraborti S
- Dimitrova D
- Xiao X
- Broder C
- Dimitrov D
- Publication year
- Publication venue
- Expert review of anti-infective therapy
External Links
Snippet
Polyclonal antibodies have a century-old history of being effective against some viruses; recently, monoclonal antibodies (mAbs) have also shown success. The humanized mAb Synagis®(palivizumab), which is still the only mAb against a viral disease approved by the …
- 241000700605 Viruses 0 title abstract description 69
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2316/00—Immunoglobulins specific features
- C07K2316/96—Antibodies with antagonisticactivity upon their specific binding to an antigen
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Clark et al. | SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms | |
Sun et al. | Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2 | |
Zhao et al. | Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability | |
Pantaleo et al. | Antibodies to combat viral infections: development strategies and progress | |
Widjaja et al. | Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein | |
Salazar et al. | Antibody therapies for the prevention and treatment of viral infections | |
Sui et al. | Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness | |
Wu et al. | Single-domain antibodies as therapeutics against human viral diseases | |
Li et al. | A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein | |
CN107667115B (en) | Human antibodies to ebola virus glycoproteins | |
Howell et al. | Cooperativity enables non-neutralizing antibodies to neutralize ebolavirus | |
Fels et al. | Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever | |
Coughlin et al. | Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential | |
Ter Meulen et al. | Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants | |
Both et al. | Monoclonal antibodies for prophylactic and therapeutic use against viral infections | |
Xia et al. | Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein | |
JP5808536B2 (en) | Anti-RSVG protein antibody | |
Allen et al. | A protective monoclonal antibody targets a site of vulnerability on the surface of Rift Valley fever virus | |
Crowe Jr | Human antibodies for viral infections | |
Prabakaran et al. | Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses | |
Williams et al. | A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo | |
Milligan et al. | Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses | |
Xu et al. | The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization | |
Strohl et al. | Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants | |
Sroga et al. | Nanobodies: a new approach for the diagnosis and treatment of viral infectious diseases |